Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies

[1]  T. Greulich,et al.  Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial , 2017, Respiratory Research.

[2]  M. R. Siddiqui,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .

[3]  A. Ismaila,et al.  Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis , 2016 .

[4]  F. Maltais,et al.  A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.

[5]  W. Fahy,et al.  Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial , 2016, Drugs in R&D.

[6]  E. Kerwin,et al.  FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[7]  Nuofu Zhang,et al.  LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD , 2015, International journal of chronic obstructive pulmonary disease.

[8]  A. Papi,et al.  INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD , 2014, European Respiratory Journal.

[9]  G. Pledger,et al.  Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.

[10]  M. Decramer,et al.  Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[11]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[12]  S. Rennard,et al.  Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease , 2008, Drugs.

[13]  S. Rennard,et al.  Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. , 2008, Drugs.

[14]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.